Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research note released on Saturday. The firm issued a sell rating on the biotechnology company’s stock.

Evogene Trading Up 16.4 %

Shares of EVGN stock opened at $1.92 on Friday. The company has a market capitalization of $10.30 million, a P/E ratio of -0.43 and a beta of 1.36. The business’s 50 day moving average is $1.75 and its two-hundred day moving average is $3.37. Evogene has a twelve month low of $1.20 and a twelve month high of $10.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.